Remibrutinib After Switching From Ocrelizumab in Relapsing Multiple Sclerosis
Tests remibrutinib pill after switching from ocrelizumab in adults with relapsing multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Key facts
- Where
- Albuquerque, Altamonte Springs, Austin, Boston, Buffalo, Burlington, Centerville, Chapel Hill, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Fargo, Farmington Hills, Fort Worth, Foxborough, Gainesville, Greenfield, Greenville, Hollywood, Irvine, Kansas City, Knoxville, Las Vegas, Maitland, Miami, Milwaukee, Naples, Olney, Orlando, Owosso, Plano, Portland, Raleigh, Richmond, Scottsdale, St Louis, Tallahassee, Tampa, Teaneck, Vero Beach, and Washington D.C., United StatesSee the 45 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Source: NCT06846281, who can take part
Where in United States
- University of New MexicoAlbuquerque, United StatesTaking people
- Neurology of Central FL Res CtrAltamonte Springs, United StatesTaking people
- Austin Regional ClinicAustin, United StatesTaking people
- Tufts Medical CenterBoston, United StatesNo longer taking part
- SUNY Buffalo The Jacobs Neuro InstBuffalo, United StatesTaking people
- Lahey Hospital and Medical CenterBurlington, United StatesTaking people
- Premier HealthCenterville, United StatesTaking people
- University of North CarolinaChapel Hill, United StatesTaking people
- Rush University Medical CenterChicago, United StatesTaking people
- University of ChicagoChicago, United StatesTaking people
- Univ of Cincinnati Medical CenterCincinnati, United StatesTaking people
- Cleveland Clinic FoundationCleveland, United StatesTaking people
- Ohio Health Research InstituteColumbus, United StatesTaking people
- Univ of Texas Southwest Med CenterDallas, United StatesTaking people
- Sanford HealthFargo, United StatesTaking people
- Michigan Institute of NeurologicalFarmington Hills, United StatesTaking people
- John Peter Smith HospitalFort Worth, United StatesTaking people
- Neurology Center of New England, PCFoxborough, United StatesTaking people
- University of FloridaGainesville, United StatesTaking people
- Center for Neurological Disorders GGreenfield, United StatesTaking people
- Premier NeurologyGreenville, United StatesTaking people
- Memorial Healthcare SystemHollywood, United StatesTaking people
- University of California, IrvineIrvine, United StatesTaking people
- University of Kansas HospitalKansas City, United StatesTaking people
- Sibyl Wray MD Neurology PCKnoxville, United StatesTaking people
- Cleveland Clinic FoundationLas Vegas, United StatesTaking people
- Neurology Associates PAMaitland, United StatesTaking people
- Elite Clinical ResearchMiami, United StatesTaking people
- Medical College of WisconsinMilwaukee, United StatesTaking people
- Aqualane Clinical ResearchNaples, United StatesTaking people
- Medstar Montgomery Medical CenterOlney, United StatesTaking people
- Advent Health OrlandoOrlando, United StatesTaking people
- Orlando Health Clinical TrialsOrlando, United StatesTaking people
- Memorial HC Ins for NeuroscienceOwosso, United StatesTaking people
- Saturn Research Solutions LLCPlano, United StatesTaking people
- Providence Neurological Services WestPortland, United StatesTaking people
- Velocity Clinical ResearchRaleigh, United StatesTaking people
- Virginia Commonwealth UniversityRichmond, United StatesTaking people
- Perseverance Research CenterScottsdale, United StatesTaking people
- WA Uni School Of MedSt Louis, United StatesTaking people
- Tallahassee Neurological ClinicTallahassee, United StatesTaking people
- University of South FloridaTampa, United StatesTaking people
- Holy Name Medical CenterTeaneck, United StatesTaking people
- Vero Beach NeurologyVero Beach, United StatesTaking people
- MedStar Washington Hospital CenterWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06846281EU 2023-509275-17-00
- Record updated
- 26 October 2026
- Original description
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).Read full original descriptionShow less
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Inclusion: Male or female aged 40 to 70 years (inclusive); Diagnosis of RMS according to the 2017 McDonald diagnostic criteria; Treated with ocrelizumab according to routine clinical practice and at standard dose; Neurologically stable within 30 days; Suitable to be switched to remibrutinib based on physician judgement or patient preference.
Exclusion: History of clinically significant Central Nervous System disease or neurological disorders; History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent; Active clinically significant systemic bacterial, viral, parasitic or fungal infections; Active, chronic disease of the immune system other than MS; Severe cardiac disease or significant findings on the ECG; History of life-threatening infusion or injection reaction related to ocrelizumab; Participants not adequately controlled on ocrelizumab (CD19+ B-cell count ≥10 cells/µL at screening); Other inclusion and exclusion criteria may apply; Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria; Participant who is unable to undergo MRI scans.